Atezolizumab (Tecentriq) and Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza) — CPB 0909 | AETNA Coverage Update

Aetna modified CPB 0909 for atezolizumab (Tecentriq) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza), effective March 17, 2026. Here's what changes for billing teams.

Aetna, a CVS Health company, updated its atezolizumab coverage policy under CPB 0909 Aetna, covering HCPCS codes J9022 and J9024 across a wide range of oncology indications. The modification expands and refines medical necessity criteria across non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, mesothelioma, alveolar soft part sarcoma, and more. If your practice or health system bills for oncology infusions under CPT 96413, 96414, or 96415, this policy affects your prior authorization workflow and claim submission process starting March 17, 2026.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Atezolizumab (Tecentriq) and Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza)
Policy Code	CPB 0909
Change Type	Modified
Effective Date	March 17, 2026
Impact Level	High
Specialties Affected	Medical oncology, hematology-oncology, infusion centers, outpatient hospital oncology
Key Action	Verify prior authorization criteria for each indication and confirm genomic testing (CPT 81235, 88271–88275) is documented before submitting claims under J9022 or J9024

---

Aetna Atezolizumab Coverage Criteria and Medical Necessity Requirements 2026

The real issue with this policy is complexity. CPB 0909 governs two products—IV atezolizumab (J9022) and the newer subcutaneous formulation atezolizumab and hyaluronidase-tqjs (J9024)—across more than a dozen tumor types. Each indication has its own medical necessity criteria. A claim that works for first-line NSCLC will fail for adjuvant HCC if your documentation doesn't match the exact language in this policy.

Precertification is required for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277 for prior authorization on atezolizumab infusions. The Tecentriq Hybreza (J9024) subcutaneous formulation follows the same prior auth path. Do not assume one precertification covers both products or both formulations.

Aetna's site of care utilization management policy also applies to both formulations. That means reimbursement can be denied not just on clinical grounds but on site-of-service grounds. Review Aetna's drug infusion site-of-care policy separately and confirm your infusion setting qualifies before the effective date of March 17, 2026.

Non-Small Cell Lung Cancer (NSCLC)

For NSCLC, Aetna's coverage policy requires no EGFR exon 19 deletions, no L858R mutations, and no ALK rearrangements as a baseline condition. The exception: if tissue is insufficient for testing, Aetna accepts that limitation. CPT 81235 covers EGFR gene analysis; CPT 88271–88275 cover FISH and in situ hybridization testing for ALK. Document these tests or document why testing was not feasible. Without that, expect a claim denial.

Within NSCLC, Aetna covers atezolizumab for:

#	Covered Indication Copy
1	Recurrent, advanced, or metastatic disease: as continued maintenance (single agent or with bevacizumab, J9035), as first-line or subsequent therapy with chemotherapy with or without bevacizumab, or as first-line single-agent therapy
2	Stage IB–III PD-L1 positive disease: as single-agent adjuvant therapy (same genomic exclusion criteria apply)
3	Recurrent, advanced, or metastatic disease: as single-agent subsequent therapy

PD-L1 status matters for adjuvant NSCLC. Make sure that result is in the record before submitting.

Small Cell Lung Cancer (SCLC)

For extensive-stage SCLC, Aetna covers atezolizumab in combination with etoposide (J9181 or J8560) and carboplatin (J9045), followed by maintenance as a single agent or with lurbinectedin (J9223). The combination regimen and the maintenance phase are both covered—but they are separate authorization events. Bill and document them separately.

Hepatocellular Carcinoma (HCC)

Aetna covers two HCC scenarios under this coverage policy:

#	Covered Indication Copy
1	First-line treatment of unresectable or metastatic HCC in combination with bevacizumab (J9035 or biosimilars Q5107, Q5118, Q5126, Q5129)
2	Adjuvant treatment following resection or ablation, also in combination with bevacizumab

The adjuvant HCC indication is the newer of the two. If your team has been billing atezolizumab only for unresectable/metastatic HCC (ICD-10 C22.0), update your workflows to include post-resection adjuvant cases. That's a real expansion of billable scenarios.

Melanoma

Aetna covers atezolizumab for BRAF V600 mutation-positive unresectable or metastatic melanoma—but only in the triplet combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf). This is not a single-agent melanoma indication. If the oncologist isn't prescribing the full triplet, this indication does not apply and the claim will not survive medical necessity review.

Mesothelioma

Coverage covers subsequent treatment of peritoneal mesothelioma, pericardial mesothelioma, or tunica vaginalis testis mesothelioma in combination with bevacizumab. Note the "subsequent" qualifier—this is not a first-line indication for mesothelioma. Document prior treatment before submitting.

Alveolar Soft Part Sarcoma (ASPS)

Aetna covers atezolizumab for unresectable or metastatic alveolar soft part sarcoma. ASPS is rare. If your center treats sarcoma, confirm the ICD-10 code maps correctly to the ASPS diagnosis before billing under this indication.

---

Aetna Atezolizumab Exclusions and Non-Covered Indications

The clearest exclusion in CPB 0909 is prior checkpoint inhibitor progression. Aetna considers members not eligible for atezolizumab if they have experienced disease progression while on any PD-1 or PD-L1 inhibitor. That list includes:

#	Excluded Procedure Copy
1	PD-1 inhibitors: nivolumab (Opdivo, J9299), pembrolizumab (Keytruda, J9271), cemiplimab (Libtayo, J9119)
2	PD-L1 inhibitors: atezolizumab (Tecentriq, J9022), atezolizumab and hyaluronidase-tqjs (J9024), avelumab (Bavencio, J9023), durvalumab (Imfinzi, J9173)

This matters for sequencing. A patient who progressed on pembrolizumab is not eligible for atezolizumab under this policy—even if the oncologist wants to try a different checkpoint. Before submitting, check the treatment history. If progression on a prior checkpoint inhibitor is in the record, Aetna will deny the claim and you will not win that appeal.

---

Coverage Indications at a Glance

---

Aetna Atezolizumab Billing Guidelines and Action Items 2026

Tecentriq billing under CPB 0909 has real claim denial risk if your team doesn't act before March 17, 2026. Here are the specific steps to take now.

Copy Action Items

If your practice treats multiple tumor types under this policy, loop in your compliance officer before March 17, 2026. The intersection of site-of-care rules, prior checkpoint exclusions, and indication-specific genomic requirements creates real exposure across a high-cost drug category.

---

CPT, HCPCS, and ICD-10 Codes for Atezolizumab Under CPB 0909

HCPCS Codes — Covered When Selection Criteria Are Met

Code	Description Copy
J9022	Injection, atezolizumab, 10 mg
J9024	Injection, atezolizumab, 5 mg and hyaluronidase-tqjs

HCPCS Codes — Combination Agents and Related Drugs

CPT Codes — Chemotherapy Administration

CPT Codes — Genomic and Molecular Testing

Key ICD-10-CM Diagnosis Codes

The full ICD-10 code set under CPB 0909 contains 445 codes. The codes above represent the primary diagnosis categories tied to covered indications. Review the full code list at app.payerpolicy.org/p/aetna/0909 to confirm all applicable diagnosis codes for your patient population.

---